@article {486, title = {UP1304, a Botanical Composition Containing Two Standardized Extracts of Curcuma longa and Morus alba, Mitigates Pain and Inflammation in Adjuvant-induced Arthritic Rats}, journal = {Pharmacognosy Research}, volume = {8}, year = {2016}, month = {February 2016}, pages = {112-117}, type = {Original Article}, chapter = {112}, abstract = {

Background: Though, the initial etiologies of arthritis are multifactorial, clinically, patients share pain as the prime complaints. Present day pain relief therapeutics heavily relies on the use of prescription and over the counter nonsteroidal anti-inflammatory drugs as the first line of defense where their long-term usage causes gastrointestinal and cardiovascular-related side effects. Hence, the need for evidence-based safer and efficacious alternatives from natural sources to overcome the most prominent and disabling symptoms of arthritis is an overdue. Here, we evaluated the anti-inflammatory and analgesic effect of UP1304, a composition that contains a standardized blend of two extracts from the rhizome of Curcuma longa and the root bark of Morus alba in adjuvant-induced arthritis models in rats. Materials and Methods: The anti-inflammatory and analgesic effects of the botanical composition were demonstrated in adjuvant-induced arthritis models in rats with oral dose ranges of 50{\textendash}200 mg/kg. Ibuprofen at a dose of 100 mg/kg was used as a reference compound. Ex vivo sulfated glycosaminoglycan inhibition assays were performed. Results: Statistically significant improvements in pain resistance, suppression of paw edema and ankle thickness were observed in animals treated with UP1304 compared to vehicle-treated diseased rats. These results were similar to those achieved by ibuprofen treatment. Inhibitions of proteoglycan degradation were observed in a range of 37.5{\textendash}61.7\% for concentration of UP1304 at 50{\textendash}200 {\textmu}g/mL when compared to interleukin-1α-exposed untreated explants. Conclusions: These data suggest that UP1304, for its analgesic and anti-inflammatory effects, could potentially be considered agent of botanical origin for the improvement of arthritis associated symptoms.

}, keywords = {Anti-inflammatory, Arthritis, Bradykinin inhibition, Chronic pain, Curcuma longa, Morus alba}, doi = {10.4103/0974-8490.172563}, author = {Mesfin Yimam and Young-Chul Lee and Breanna Moore and Ping Jiao and Mei Hong and Jeong-Bum Nam and Mi-Ran Kim and Tae-Woo Kim and Hyun-Jin Kim and Eu-Jin Hyun and Min Chu and Lidia Brownell and Qi Jia} } @article {499, title = {UP1306, a Botanical Composition with Analgesic and Anti-inflammatory Effect}, journal = {Pharmacognosy Research}, volume = {8}, year = {2016}, month = {May 2016}, pages = {186-192}, type = {Original Article}, chapter = {186}, abstract = {

Background: Pain, one of the cardinal signs of inflammation, is the most common clinical manifestations of arthritis. Conventional pain relief therapy heavily relies on the use of prescription and over the counter nonsteroidal anti-inflammatory drugs as the first line of defense where their long-term usage causes deleterious gastrointestinal and cardiovascular-related side-effects. Hence, there is an equivocal need for evidence-based safer and efficacious alternatives from natural sources to overcome the most prominent and disabling symptoms of arthritis. Materials and Methods: Carrageenan-induced rat paw edema and abdominal constriction (writhing{\textquoteright}s) assays in mouse were used to evaluate the anti-inflammatory and analgesic effects of UP1306, a composition that contains a standardized blend of extracts from the heartwood of Acacia catechu and the root bark of Morus alba administered orally at dose ranges of 100{\textendash}300 mg/kg. Cyclooxygenase (COX) and lipoxygenase (LOX) inhibition assays were carried out to determine the IC50 of Acacia and Morus extracts. The merit of combining these two extracts was also assessed. Results: Statistically significant improvement in pain resistance and suppression of edema were observed in animals treated with UP1306, when compared to vehicle-treated diseased rats and mice. Results from the high dose of UP1306 (300 mg/kg) were similar to those achieved by ibuprofen treatment at a dose of 200 mg/kg in early hours of treatment. In vitro, UP1306 showed dose-dependent inhibition of the enzymatic activities of COX and LO with IC50 values of 20.9 μg/mL, 49.2 μg/mL, and 11.1 μg/mL in COX-1, COX-2, and 5{\textquoteright}-LO, respectively. Conclusions: These data suggest that UP1306, analgesic, and anti-inflammatory agent of botanical origin with dual COX-LO inhibition activity, could potentially be used to alleviate symptom associated to osteoarthritis.

}, keywords = {Acacia catechu, cyclooxygenase-LO dual inhibition, inflammatory pain, Morus alba, osteoarthritis}, doi = {10.4103/0974-8490.182918}, author = {Mesfin Yimam and Young-Chul Lee and Ping Jiao and Mei Hong and Jeong-Bum Nam and Lidia Brownell and Eujin Hyun and Qi Jia} }